Language:
Instant News and Commentaries
2026-11-20
16:39
Vitasoy Announces Business Results for 1H FY2026/2027

Financial Highlights

6 months ended

30 September 2026

1H FY2026/27

HK$ Mn

1H FY2025/26

HK$ Mn

Change

Change -

Net of

currency

impact

Revenue

3,337

3,227

+3 %

-1 %

Gross Profit

1,733

1,648

+5 %

+1 %

Gross Profit Margin

51.9 %

51.1 %

+0.8% pts

+0.9% pts

Profit From Operations

263

247

+7 %

+2 %

EBITDA

478

479

On par

-4 %

Profit Attributable to

Equity Shareholders of

the Company

185

172

+8 %

+3 %

Basic Earnings per

Ordinary Share (HK

cents)

18.2

16.2

+12 %

+8 %

HONG KONG, Nov. 20, 2026 /PRNewswire/ -- Vitasoy International Holdings Limited ("Vitasoy" or the "Company", together with its subsidiaries, the "Group", Stock Code: 00345) today announced its interim results ended 30 September 2026 ("the interim financial period").

In the interim financial period, the Group's revenue increased by 3% to HK$3,337 million, supported by favourable foreign exchange translation movements. The Group's gross profit margin rose steadily to 51.9%, mainly attributable to the impact of favourable foreign exchange movements, effective raw material cost management and improved operational efficiency. Profit attributable to equity shareholders of the Company increased by 8% to HK$185 million.

Mr. Winston Yau-lai Lo, Executive Chairman of Vitasoy International Holdings Limited, said at the press conference today, "We will continue to evolve our business model to improve performance, with a deliberate focus on strengthening the Chinese Mainland operation. We will expand our presence in the snack channel and improve our execution in the declining general trade segment. Intensifying price competition, elevated oil prices and a restructuring of the Australian business that refocuses on ambient products is expected to have a significant negative impact on our profitability in the second half of the financial year. Nevertheless, we remain committed to driving down costs and operating with a high level of efficiency to generate sustainable long-term returns for shareholders."

Based on the Group's financial performance and cash position, the Board of Directors has declared an interim dividend of HK4.0 cents per ordinary share (previous interim financial period: HK4.0 cents per ordinary share), payable on 18 December 2026.

Chinese Mainland –
Slight decline in revenue in local currency terms with a double-digit operating profit margin; improving sales performance via evolving channel mix following strengthened commercial leadership capabilities.

In the Chinese Mainland, the snack channel achieved double-digit growth year-on-year, a strong indicator of a preference for the brands among consumers, although this was offset by the declining general trade. Meanwhile, despite the market decline of plant milk in grocery channels, VITASOY gained market share in both the soy milk and plant milk categories during the interim financial period.

To maintain leadership in this competitive market environment, the Group strengthened the internal leadership, execution and innovation capabilities to win customers and capture emerging growth opportunities. The portfolio was enriched with VITASOY Jasmine Tea Soyabean Milk and VITASOY Coffee Latte Flavoured Soyabean Milk, as well as VITA Da Hong Pao Finger Lime Lemon Tea to broaden consumption occasions.

Through proactive cost management and enhanced operational efficiency, Chinese Mainland expanded the operating profit margin to 13% during the interim financial period.

Hong Kong Operation (Hong Kong SAR[1], Macau SAR[2] and Exports) –
Solid leadership in soy and plant milk beverages in Hong Kong SAR supported by strong brand heritage, though performance was slightly offset by weaker demand in the Macau SAR business.

The Hong Kong Operation maintained its market-leading position in the Hong Kong SAR and achieved stronger performance in export markets. However, overall business results were tempered by softer performance in the Macau SAR operations.

The long-standing brand heritage and pervasive presence in the Hong Kong SAR, together with effective product strategies and operational excellence, accounted for the stable performance achieved during the interim financial period. Leadership was maintained in the non-alcoholic beverage segment, with dominant market shares in the soy and plant milk categories and steady expansion in the ready-to-drink tea category.

Recent product innovations received a positive reception across key segments, including VITASOY Jasmine Tea Soyabean Milk, VITASOY Coffee Latte Flavoured Soyabean Milk and VITASOY CALCI-PLUS 15g Protein Soya Milk in plant-based milk, alongside VITA Da Hong Pao Finger Lime Lemon Tea, VITA Fresh Tea, and VITA No Sugar Tea in the tea portfolio. In particular, the revamped visual identity and packaging of No Sugar Tea offerings helped renew consumer interest and supported strong sales momentum.

Exports to the US market demonstrated encouraging growth after the stabilisation of tariffs, supported by a pipeline of proven product innovations and a localised marketing campaign. Meanwhile, the Vitaland business recovered mainly due to improved performance in tuckshops and a higher number of school days.

In Macau SAR, performance was constrained by softer demand and mounting price pressure from new entrants as well as established competitors. Following the implementation of a strengthening plan to adjust pricing and enhance product visibility, the business in this market has begun to show signs of recovery.

Australia and New Zealand –
Intensified price competition in a mature plant milk market and higher oil prices led to lower Australian dollar sales and a higher operating loss.

In Australia, intense market competition in the mature plant-based milk category and cautious household spending moderated topline recovery. Concurrently, New Zealand's revenue growth was offset by foreign exchange depreciation.

During the interim financial period, gross profit margin improved, supported by a favourable net sales price variance and lower raw material costs. However, operating profit recovery was hindered by higher packaging and transportation costs from rising oil prices, coupled with foreign currency fluctuations. We prioritised marketing initiatives to support the brand campaign and a packaging refresh, successfully increasing brand awareness and strengthening consumers' perceptions of the products' health benefits among plant-based milk consumers.

Singapore –
Robust revenue growth driven by strong demand for the tofu and beverage offerings.

Robust demand for Vitasoy's tofu and beverage offerings was a key driver of business growth for the Singapore business. Domestic sales gained positive momentum, led by volume expansion across both categories. Total revenue was up by 9% in local currency terms, accompanied by enhanced operating profitability.

The Philippines (Non-Consolidated Joint Venture) –

The joint venture with Universal Robina Corporation in the Philippines will continue to advance towards its long-term growth potential. Supported by strong in-store visibility and execution amid the growth of the plant-based milk segment in the Philippines, Vitasoy remains confident in its ability to scale up the operation and strengthen market presence.

For more details, please refer to the following documents:

  • Announcement of interim results ended 30 September 2026:
    Link
  • Photos download:
    Link

Vitasoy management presents its VITASOY CALCI-PLUS 15g Protein Soya Milk in Original and Chocolate Flavour at the press conference. (From left) Mr. Roberto Guidetti, Group Chief Executive Officer; Mr. Winston Lo, Executive Chairman; Ms. May Lo, Executive Deputy Chairman; and Ms. Ian Ng, Group Chief Financial Officer.
Vitasoy management presents its VITASOY CALCI-PLUS 15g Protein Soya Milk in Original and Chocolate Flavour at the press conference. (From left) Mr. Roberto Guidetti, Group Chief Executive Officer; Mr. Winston Lo, Executive Chairman; Ms. May Lo, Executive Deputy Chairman; and Ms. Ian Ng, Group Chief Financial Officer.

Vitasoy launched VITASOY CALCI-PLUS 15g Protein Soya Milk in Original and Chocolate Flavour.
Vitasoy launched VITASOY CALCI-PLUS 15g Protein Soya Milk in Original and Chocolate Flavour.

Note:

[1] "Hong Kong SAR" stands for the Hong Kong Special Administrative Region of the People's Republic of China.

[2] "Macau SAR" stands for the Macao Special Administrative Region of the People's Republic of China.

About Vitasoy

Vitasoy International Holdings Limited is a leading manufacturer and distributor of plant-based food and beverages. Established in 1940 by the late Dr. Kwee-seong Lo in Hong Kong China, the Company strives to promote sustainable plant-based nutrition through provision of a variety of high-quality products with Nutrition, Taste and Sustainability as the guidelines for its portfolio offerings. Currently, Vitasoy has operations in China, including the Chinese Mainland and Hong Kong Special Administrative Region, Australia, Singapore and the Philippines. Its products are available in about 40 markets worldwide.

Vitasoy is listed on the main board of the Hong Kong Stock Exchange (00345.HK) and included as a constituent of Morgan Stanley Capital International (MSCI) Hong Kong Small Cap Index, Hang Seng Composite Index and Hang Seng Corporate Sustainability Benchmark Index, among others.     

Vitasoy website: www.vitasoy.com

 

Information Provided by PR Newswire [Disclaimer]
16:33
維他奶公佈2026/2027年度上半年業績

財務摘要 

截至2026年9月30日止
之
6個月 

2026/27年度

上半年 

港幣百萬元 

2025/26年度
上半年
 

港幣百萬元 

變化 

變動—

撇除匯率影響 

收入 

3,337

3,227

+3 %

-1 %

毛利 

1,733

1,648

+5 %

+1 %

毛利率 

51.9 %

51.1 %

+0.8個百分點

+0.9個百分點

經營溢利 

263

247

+7 %

+2 %

未計利息收入、融資成本、
所得稅、折舊及攤銷費用前
盈利(EBITDA) 

478

479

持平

-4 %

本公司股權持有人應佔溢利

185

172

+8 %

+3 %

每股基本盈利(港仙) 

18.2

16.2

+12 %

+8 %

香港2026年11月20日 /美通社/ -- 維他奶國際集團有限公司(「維他奶」或「公司」,連同其附屬公司為「集團」,股份代號:00345)今日公佈其截至2026 年9月30日止之中期業績(「中期財務期間」)。 

於中期財務期間,集團收入增加3%至港幣33.37億元,受惠於有利的外匯匯率變動。集團的毛利率穩定上升至51.9%,主要受有利的外匯匯率變動、有效的原材料成本管理及營運效率改善所帶動。本公司股權持有人應佔溢利增加8%至港幣1.85億元。

維他奶國際集團有限公司執行主席羅友禮先生今天於業績發佈會上表示:「我們將繼續推進業務模式轉型以提升表現,並重點加強中國內地業務。維他奶將進一步拓展零食渠道的市場覆蓋,同時改善表現下滑的傳統零售業務的執行力。我們預期價格競爭加劇、油價高企、以及澳洲業務重組以重新聚焦常溫產品,將對本財政年度下半年的盈利能力構成顯著的負面影響。儘管如此,我們繼續致力減低成本並以高效營運,為股東締造可持續的長期回報。」

基於集團的財務表現及現金狀況,董事會宣派中期股息每股普通股4.0港仙(去年中期財務期間:每股普通股4.0港仙),將於2026年12月18日派付。

中國內地 —
以當地貨幣計算,收入輕微下跌,仍錄得雙位數的經營利潤率;通過優化銷售渠道組合及加強商業領導能力,提升銷售表現。

在中國內地,零食渠道按年實現雙位數增長,充分印證消費者對於品牌的偏好持續提升,惟增長被傳統零售渠道表現下滑所抵銷。與此同時,儘管傳統食品零售渠道的植物奶市場有所下滑,維他奶的豆奶及植物奶類產品的市場份額仍於中期財務期間錄得增長。

為了在此競爭激烈的市場環境保持領先,維他奶持續強化內部領導力、執行力與創新能力,以贏取客戶及把握新的增長機遇。同時,集團進一步豐富產品組合,推出維他奶茉莉花茶豆乳、維他奶咖啡拿鐵味豆乳,以及維他大紅袍手指檸檬檸檬茶,以創造更多元化的飲用場景。

透過積極的成本管理及提升經營效率,中國內地於中期財務期間將經營利潤率擴大至13%。

香港業務(香港特別行政區[1]、澳門特別行政區[2]及出口)—
憑藉強大的品牌傳承,香港特別行政區的豆奶及植物奶飲品保持穩健的領先地位,惟該表現稍被澳門特別行政區的疲弱需求所抵銷。

香港業務於香港特別行政區維持市場領導地位,出口業務錄得更強勁的表現。然而,澳門特別行政區業務表現較為疲弱,影響了整體的業績增長。

憑藉於香港特別行政區悠久的品牌傳承與廣泛的市場覆蓋,配合有效的產品策略與卓越營運,維他奶於中期財務期間錄得穩健表現。香港業務於非酒精飲品業務保持領先地位,主導豆奶及植物奶類產品的市場份額,並穩步拓展即飲茶類產品業務。

近期的產品創新在各個主要市場均獲得正面迴響,包括植物奶類別中的維他奶茉莉花茶豆乳、維他奶咖啡拿鐵味豆乳及維他奶鈣思寶15克蛋白質豆乳,以及茶類的維他大紅袍手指檸檬檸檬茶、維他新鮮茶及維他無糖茶。其中,無糖茶系列通過煥新的視覺形象及包裝設計,有助提升消費者興趣,並帶動銷售保持強勁的增長勢頭。

隨著關稅趨於穩定後,出口至美國的業務展現令人鼓舞的增長,受益於一系列受市場認可的產品創新及本地化市場推廣活動。與此同時,維他天地業務復甦,主要由學校小食部表現提升及上課天數增加所帶動。

澳門特別行政區方面,市場需求疲軟,加上新進及現有競爭對手帶來的價格壓力加劇,影響業務表現。隨著集團實施業務改善計劃,調整定價並提高產品曝光度,當地業務已逐漸展現復甦跡象。

澳洲及新西蘭 –
植物奶市場已經成熟,而且價格競爭加劇,加上油價上升,導致以澳幣計算的銷售額下降及經營虧損上升。

在澳洲,植物奶類產品市場已經成熟,而且競爭激烈,加上家庭消費態度審慎,令收入復甦步伐放緩。同時,新西蘭的收入增長受外匯貶值所抵銷。

於中期財務期間,毛利率有所上升,受益於淨售價提升及原材料成本下降。然而,油價上升令包裝及運輸成本增加,加上外匯波動,阻礙經營溢利的復甦。集團優先投放資源於市場推廣計劃,支持品牌活動及包裝改良,成功提升品牌知名度,並加深植物奶消費者對產品健康效益的認知。

新加坡 –
豆腐及飲品需求強勁,帶動收入錄得強勁增長。

豆腐及飲品需求強勁,成為新加坡業務增長的主要動力。當地銷售勢頭向好,主要由該兩類產品的銷量增長所帶動。以當地貨幣計算,總收入上升9%,經營盈利能力亦有所提升。

菲律賓(非綜合入賬合營公司) —

集團與Universal Robina Corporation成立的合營公司將繼續朝著實現長遠增長潛力的方向邁進。隨著菲律賓植物奶市場持續增長,配合強大的店內曝光度與卓越的執行力,集團有信心可擴大業務規模及提升市場覆蓋率。

詳情請參閱以下文件:

  • 截至2026年9月30日止之中期業績公告:
    按此
  • 下載圖片:
    按此

圖片一:維他奶管理層在新聞發佈會上展示維他奶鈣思寶15克蛋白質豆乳(原味及朱古力口味)。圖為(左起)集團行政總裁陸博濤先生、執行主席羅友禮先生、執行副主席羅其美女士,及集團首席財務總監吳茵虹女士。
圖片一:維他奶管理層在新聞發佈會上展示維他奶鈣思寶15克蛋白質豆乳(原味及朱古力口味)。圖為(左起)集團行政總裁陸博濤先生、執行主席羅友禮先生、執行副主席羅其美女士,及集團首席財務總監吳茵虹女士。

圖片二:維他奶推出維他奶鈣思寶15克蛋白質豆乳(原味及朱古力口味)。
圖片二:維他奶推出維他奶鈣思寶15克蛋白質豆乳(原味及朱古力口味)。

關於維他奶

維他奶國際集團有限公司是一間專注植物食品及飲品的生產及分銷商,總部設於中國香港。自維他奶於 1940 年由羅桂祥博士創立以來,一直致力以各種高品質產品,以營養、美味及可持續發展作為開拓產品方針,從而推廣可持續的營養,並重視社會責任及致力回饋社會。目前,維他奶旗下產品行銷全球約 40 個市場,在中國 (包括中國內地及香港特別行政區)、澳洲、新加坡及菲律賓設有營運基地。

維他奶國際集團有限公司(00345.HK)在香港聯合交易所主板上市,並獲納入多個指數類別,包括摩根士丹利資本國際指數(MSCI) 香港小型股指數、恒生綜合指數及恒生可持續發展企業基準指數。

維他奶公司網站:www.vitasoy.com

附註:
[1] 「香港特別行政區」指中華人民共和國香港特別行政區。
[2] 「澳門特別行政區」指中華人民共和國澳門特別行政區。

Information Provided by PR Newswire [Disclaimer]
14:57
寧德時代在伊斯坦布爾開設土耳其首個寧家服務體驗中心

土耳其伊斯坦布爾2026年11月20日 /美通社/ -- 11月19日,寧德時代在土耳其的首個寧家服務體驗中心正式開業。該設施是土耳其首個專業電池倉維修中心及銷售服務一體化樞紐,標誌著寧德時代在拓展本地化新能源後市場服務網絡、支持該國向清潔能源體系轉型方面又邁出一步。


土耳其地處歐洲、亞洲和中東的交匯點,是區域經濟樞紐,擁有快速增長的電動汽車市場和迅速擴張的儲能行業,向清潔能源的轉型正推動對專業電池支持的需求。其《國家能源2040》規劃提出在2040年前實現2000萬輛電動汽車保有量以及140 GWh儲能容量的目標。在此背景下,寧家服務為道路車輛和電網提供全生命周期電池服務,進一步鞏固這一轉型所依賴的基礎設施。

寧家服務體驗中心位於伊斯坦布爾,是寧德時代與Ascendum集團旗下Ascendum Türkiye合作的重要里程碑,提供全面的全生命周期售後支持,培養本地技術人才,並加速先進電氣化和儲能解決方案的部署。

伊斯坦布爾體驗中心占地超過1,200平方米,設有電池檢測、診斷、維修、保養和翻新服務區,以及展覽零售區、培訓室和客戶休息區。展覽零售區展示寧德時代在電動出行和儲能領域的系統級能力,包括磐石底盤、便攜式電源、電池保護板及儲充一體化單元。該中心既是區域的本地化服務樞紐,也是連接生態合作伙伴的平台。 

提供全方位的新能源後市場服務體系

作為寧德時代獨立的後市場服務品牌,寧家服務提供一站式、全生命周期的電池服務體系,涵蓋電池診斷、維修、保養、翻新、培訓、回收及售後物流倉儲。依托寧德時代深厚的研發實力與極限制造能力,其服務產品品類覆蓋乘用車、商用車和儲能系統,為區域新能源服務交付樹立新標桿。

這一能力通過行業規模最大的售後服務網絡來實現:

  • 遍布80多個國家和地區的1,429個專業服務網點,目標到2027年覆蓋100個國家和地區,到2030年達到10,000個服務網點;
  • 超過9,900名服務工程師和10,000多名獲新能源售後服務認證的技術人員,海外市場實行24小時響應機制;
  • 深度維修能力通過95個中心組成的網絡實現,覆蓋76.8%的電動汽車車型和90%的維修作業;
  • 智能鷹眼系統已在150多個維修設施投入使用,提供全程可追溯與質量控制;
  • 智能電池檢測系統支持精準的電池健康診斷,可將電池老化速度最多降低9.5%;
  • 參與制定或修訂70多項行業標準,在全球擁有200多項授權專利。

強化本地合作與服務能力

寧德時代正通過加強基礎設施建設和建立市場合作伙伴關系,拓展其本地布局。通過將寧德時代的技術專長與Ascendum集團67年的工業傳承及強大的本地網絡相結合,伊斯坦布爾體驗中心使寧德時代能夠服務土耳其全境的客戶,讓其專業經驗與快速響應能力貼近電池的實際使用場景。

該中心支撐起覆蓋土耳其全境的服務網絡,並配備一支由寧德時代認證工程師組成的團隊。它同時也是該網絡的培訓基地,技術人員在此按寧德時代標準接受培訓和獲得認證後,才能提供客戶電池服務,從而為市場培養並持續輸送本地電池服務技能人才。

Ascendum Türkiye首席執行官Tolga Polat表示:「土耳其首個寧家服務體驗中心的開業,是我們與寧德時代戰略合作的重要里程碑,也是Ascendum Green.Shift旗下推出的首個業務舉措。通過將寧德時代先進的電池技術,與Ascendum長期積累的技術服務專長和以客戶為中心的理念相結合,我們致力於在土耳其全境提供可靠、高質量的售後解決方案。我們正投資於本地技術能力,培養專業團隊,強化服務基礎設施,以滿足能源和出行行業不斷變化的需求。展望未來,我們的目標是逐步將服務網絡擴展至全國,構建可持續的生態體系,為客戶創造長期價值,並支持土耳其的能源轉型。」

寧德時代銷售與營銷聯席總裁、商用應用與後市場業務總裁Bruce Li稱:「土耳其已駛入電動化快車道,後市場服務需求也將隨之增長。作為我們在該國的首個寧家服務體驗中心,它將寧德時代的技術、我們的培訓標準以及Ascendum的本地覆蓋能力相結合,讓道路與電網兩端的客戶都能享受到本地人員與本地備件服務。以此為基礎,我們將繼續把服務網絡擴展至土耳其各地,與國家能源2040目標協同並進,並為能源轉型提供經得起時間考驗的服務支撐。」


展望未來,寧家服務將繼續在維修技術、服務模式和網絡擴展方面推動創新。伊斯坦布爾體驗中心是土耳其市場的起點,後續將進一步推進網絡布局與能力建設。 

Information Provided by PR Newswire [Disclaimer]
13:05
Trip.Best Unveils Its Biggest Global Rankings Yet, Covering All Seven Continents for the First Time

Global travel rankings grow to 98 annual lists across nine regions and 22 languages, with the first standalone Oceania lists.

SYDNEY, Nov. 20, 2026 /PRNewswire/ -- Trip.Best, the global travel rankings from Trip.com Group, launched its 2027 Annual Rankings in Sydney, extending coverage to all seven continents for the first time. Unveiled at The Dome, Sydney Showground, as part of Trip.com Group's Global Partner Summit, this year's edition grows from 85 to 98 annual rankings and from five to nine regions, across 22 languages.

Oceania, Africa and Antarctica join as new regions, and the Americas are now split into North and South America. In total, the 2027 Annual Rankings feature more than 3,700 entries across 112 countries and regions, spanning hotels, attractions, nightlife, dining and destinations. Winners were recognised at the Global 100 Awards Ceremony.

Oceania Steps Into the Global Spotlight With Eight Standalone Rankings

Oceania Steps Into the Global Spotlight With Eight Standalone Rankings
Oceania Steps Into the Global Spotlight With Eight Standalone Rankings

For the first time, Trip.Best publishes eight standalone Oceania 50 lists, recognising more than 250 hotels, attractions, restaurants and experiences across Australia, New Zealand and the Pacific islands. The lists cover scenic hotels, must-see and family attractions, nightlife, fine dining and must-visit restaurants, with ski-resort and hot-spring rankings reflecting the region's year-round appeal.

Top-ranked winners include:

  • Scenic Hotel: Four Seasons Resort Bora Bora, followed by Park Hyatt Sydney and Rosewood Kauri Cliffs in New Zealand.
  • Best Things to Do: Sydney Opera House, followed by Bora Bora and the TSS Earnslaw Steamship in Queenstown.
  • Fine Dining: Essence in Queenstown, followed by Bennelong in Sydney and Jano Bistro in Wellington.
  • Must-Visit Restaurant: Fergburger in Queenstown, followed by Bar Totti's in Sydney and Depot in Auckland.

Global 100 Lists Honour Leading Hotels, Sights and Restaurants

Global 100 Lists Honour Leading Hotels, Sights and Restaurants
Global 100 Lists Honour Leading Hotels, Sights and Restaurants

At global level, the Global 100 lists are led by:

  • Luxury Hotel: Hôtel de Crillon, A Rosewood Hotel in Paris, followed by Raffles Singapore and Le Bristol Paris.
  • Scenic Hotel: Il San Pietro di Positano in Italy, followed by Cheval Blanc Randheli in the Maldives and Le Sirenuse in Positano.
  • Best Things to Do: The Louvre in Paris.
  • Fine Dining: DiverXO in Madrid, followed by L'Arpège in Paris and Disfrutar in Barcelona.

New Wonders Lists Showcase What Makes a Destination Distinctive

New Wonders Lists Showcase What Makes a Destination Distinctive
New Wonders Lists Showcase What Makes a Destination Distinctive

Trip.Best also introduces Wonders - a new collection of rankings aimed at international travellers seeking inspiration for their next destination. Each list is built on what makes a destination distinctive and what gives it an edge over others across markets. The collection comprises 49 themed lists across 10 countries and four categories (hotels, attractions, food and destinations) and is available in 22 languages.

Australia features in two lists: Native Wildlife Conservation Encounters, led by Currumbin Wildlife Sanctuary, and Outdoor Adventures, led by Cairns. Global Wonders lists include Diving Experiences, Ski Towns and Sunset Views.

About Trip.com Group

Trip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com. Follow us on: X, Facebook, LinkedIn, and YouTube.

Information Provided by PR Newswire [Disclaimer]
13:00
Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

SHANGHAI, Nov. 20, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).

ASCEND's primary efficacy endpoint is the change in best-corrected visual acuity (BCVA) from baseline to Week 36 versus aflibercept dosed every eight weeks. The goal of the ASCEND study is to determine the dose(s) to advance into VIS-101's global Phase 3 program based on safety, efficacy and durability.

VIS-101 is a purpose-designed tetravalent, dual VEGF-A x ANG-2 inhibitor in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.

Wet AMD affects more than 20 million people globally[1]. In China, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment.

"Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101. With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control. ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.

Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients."

On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.

About the ASCEND Phase 2b Trial

ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b study (NCT07798375) to evaluate the safety and efficacy of VIS-101 (aka AM712 or ASKG712) in approximately 244 treatment naïve patients with wet AMD in China. Patients will be randomized to either 6 mg or 9 mg VIS-101, or 2 mg aflibercept, a standard-of-care anti-VEGF therapy. All patients will initially receive three monthly doses of either VIS-101 or aflibercept and can then be retreated based on protocol-specified retreatment criteria that are the same for all groups up to Month 9. The main objectives are to determine the dose(s) to be studied in Phase 3 clinical trials and establish the initial durability with treatment intervals up to seven months after three loading doses.

About VIS-101

VIS-101 (also known as ASKG712 or AM712), is a dual VEGF-A X ANG-2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101's bispecific, tetravalent design format provides more binding sites and increased VEGF-A and ANG-2 affinity and avidity, for rapid, robust and durable responses. VIS-101 has completed initial safety and dose-escalation studies in both the US and China and a randomized, dose-ranging 2a study in China (NCT05456828). VIS-101 is currently being evaluated in the dose-determining Phase 2b ASCEND study, with initiation of the global Phase 3 program planned as early as 2027.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company owns a global manufacturing base of commercial scale in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with China, EU, and WHO standards.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Its pharmaceutical distribution capabilities further complement its existing manufacturing and commercialization operations, supporting efficient product supply and delivery to the market.

Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.

For more information, please visit the Company's website: www.everestmedicines.com. 

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Source information:

  1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62 (14): 26. doi: 10.1167/iovs.62.14.26

Information Provided by PR Newswire [Disclaimer]
12:59
雲頂新耀宣佈VIS-101治療濕性AMD的IIb期ASCEND臨床研究完成首例患者給藥

上海2026年11月20日 /美通社/ -- 雲頂新耀(HKEX 1952.HK),是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司,宣佈VIS-101治療濕性年齡相關性黃斑變性(濕性AMD)的IIb期ASCEND臨床研究已完成首例患者給藥。

ASCEND研究是一項隨機IIb期臨床研究,旨在綜合評估VIS-101的安全性、療效及療效持久性,確定後續全球III期臨床開發所採用的劑量。該研究計劃在中國納入244例未接受過治療的濕性AMD患者,設置VIS-101 6 mg和9 mg兩個劑量組,並以阿柏西普2 mg(每8周給藥一次)作為活性對照。主要療效終點為第36周時最佳矯正視力(BCVA)相較基線的變化。

在此前一項隨機、劑量探索性IIa期臨床研究中,VIS-101在濕性AMD患者中展示出起效迅速、強效持久的治療反應,及良好的安全性及耐受性。其中,6 mg 組中約半數初治受試者在第36周前無需補救治療。

VIS-101作為一款靶向VEGF-A和ANG-2的新型四價雙特異性抗體,具備同類最佳潛力,有望為濕性AMD患者帶來新的治療選擇,並展現出在糖尿病性黃斑水腫(DME)、視網膜靜脈阻塞(RVO)等其他視網膜血管疾病領域進一步探索的前景。

濕性AMD等視網膜血管疾病患者群體龐大,目前全球有超過2,000萬濕性AMD患者[1]。在中國,濕性AMD和DME的現有及新增患者人數已超過1,500萬,每年新增約60萬例,而目前接受抗VEGF治療的患者人數僅約50萬,存在巨大的臨床需求。

雲頂新耀首席執行官羅永慶表示:「濕性AMD等視網膜血管疾病患者群體龐大,不僅影響患者視力和生活質量,也帶來長期疾病負擔,患者對更優治療方案的需求尚未得到充分滿足。VIS-101在治療濕性AMD的IIa期臨床研究中展示出起效迅速、強效持久的治療反應,同時安全性和耐受性良好。

IIb期ASCEND臨床研究完成首例患者給藥,是VIS-101臨床開發中的重要進展。該研究以現有標準療法為對照,將進一步評估VIS-101的療效、安全性及持久性,重點探索其延長給藥間隔、實現持久疾病控制的潛力,並為後續全球臨床開發提供重要依據。眼科是雲頂新耀聚焦的核心治療領域之一,憑借在中國和亞洲市場的深厚積累,我們將加快推進VIS-101的臨床開發進程,讓這款創新療法惠及更多患者。」

關於IIb期ASCEND臨床研究

ASCEND是一項隨機、四重盲法、陽性藥物對照的頭對頭IIb期臨床研究(NCT07798375),旨在評估VIS-101(又稱AM712或ASKG712)在中國約244例未經治療的濕性年齡相關性黃斑變性(濕性AMD)患者中的安全性和有效性。

研究將患者隨機分配至VIS-101 6 mg組、VIS-101 9 mg組或阿柏西普(aflibercept)2 mg組。阿柏西普是一種抗VEGF標準治療藥物。所有患者首先接受連續三個月、每月一次的VIS-101或阿柏西普治療,隨後根據研究方案預設的再治療標準決定後續給藥。直至第9個月,各治療組均採用相同的再治療標準。

本研究旨在確定適用於III期臨床試驗的VIS-101劑量,並初步評估其給藥持久性,探索在完成三次負荷給藥後最長可達七個月的給藥間隔。

關於VIS-101

VIS-101(又名ASKG712或AM712)是一款靶向 VEGF-A/Ang-2的新型雙特異性融合蛋白,具備同類最佳潛力,擬用於治療濕性年齡相關性黃斑變性(濕性AMD)、糖尿病性黃斑水腫(DME)、視網膜靜脈阻塞(RVO)。其雙特異性、四價結構擁有更多結合位點,對VEGF-A 和ANG-2的親和力與結合力更強,可帶來起效迅速、強效持久的治療應答。目前VIS-101已在美國和中國完成初步安全性及劑量遞增研究,並在中國完成隨機、劑量探索IIa期研究(NCT05456828),IIb期ASCEND臨床研究正在積極推進中,全球III期臨床研究最早於2027年啟動。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司,致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地,並依據中國、歐盟和WHO標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM(心血管、腎臟及代謝)等疾病治療領域,已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台。公司已建立涵蓋藥品生產製造、經營流通及商業化運營的業務體系,並具備相應的藥品生產和經營資質,進一步完善了從生產端到市場端的業務佈局,為藥品供應、分銷及商業化業務的持續拓展提供支持。

同時,公司依托擁有全球權益的自研mRNA平台為基礎,持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線,同時通過引進及生態孵化潛力平台,拓展研發能力,同時強化全球化佈局,加快國際化發展進程。

更多信息,請訪問公司官網:www.everestmedicines.com。

前瞻性聲明

本新聞稿所發佈的信息中可能會包含某些前瞻性表述,乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期,可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證,會受到風險、不確定性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響,實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務,除非法律要求。

參考文獻

1. Invest Ophthalmol Vis Sci. 2021 Nov 24; 62(14): 26. doi: 10.1167/iovs.62.14.26

Information Provided by PR Newswire [Disclaimer]
12:05
IMF Managing Director: AI Investment Adjustment Not Yet Over

Concerns over returns on AI investment intensified global market volatility. International Monetary Fund (IMF) Managing Director Kristalina Georgieva said the IMF had previously expected an adjustment in AI-related capital markets due to overheated market sentiment, but no major correction has emerged so far and she believed more market adjustments will come in the future.

According to the IMF's conservative estimates, AI could contribute 0.5 ppts to global economic growth, Georgieva said, adding that this year marks the first time in history that AI has had a substantive impact on global economic growth.

When asked about the economic impact of US restrictions on chip exports to SE Asian countries, she said the threat is not enormous at present. However, the greater risk would be technological fragmentation forcing countries to choose sides, which could lead to more serious consequences.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
10:40
Anthropic Debut Ends Up 17%; NVIDIA Slides 40% from Peak in Over a Mth

Anthropic, PBC (ANT.US) priced its IPO at USD83 per share, valuing the developer of chatbot Claude at about USD1.5 trillion. The market is keeping a close tab as to whether its first trading day performance can create a more optimistic atmosphere on Wall Street than the earnings released by NVIDIA (NVDA.US). Anthropic shares closed at USD97.17 on Thursday (19th), up 17.1% from the IPO price.

NVIDIA reported strong results this week, including quarterly sales guidance of USD130 billion. However, the stock still closed down 3.3% on Thursday (19th), about 40% below the record peak reached in early October. Market participants expected strong demand for Anthropic shares to help revive sentiment toward tech stocks.

The market stayed positive on Anthropic's first trading day prospects, particularly for tech stocks. Goldman Sachs European equities trading head Rich Privorotsky said "today feels important".

The AI industry remains highly vibrant. Google is launching a multi-million-dollar project to melt rocks near a volcano in Oregon in an attempt to create clean energy supplies for its data centers.

Federal Reserve Governor Christopher Waller said the central bank may need to shock market participants to break inflation expectations, which could require more than three interest rate hikes.

A series of major technology outages over the past week has prompted lawmakers in Washington to seek answers. Meanwhile, hedge fund Bridgewater Associates said a specific inflection point for exponential growth in cyber incidents has already emerged.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:09
US Approves Shipment of ~900,000 Advanced AI Chips to CN within 6 Mths; TENCENT Receives 150,000 Units, BABA-W Gets 75,000

The US House Foreign Affairs Committee said the US government approved the shipment of nearly 900,000 advanced AI chips manufactured by NVIDIA (NVDA.US) and Advanced Micro Devices (AMD.US) to Chinese companies between December 2025 and May 2026.

Among them, 75,000 units were shipped to BABA-W (09988.HK), 150,000 units to TENCENT (00700.HK), 43,000 units to BIDU-W (09888.HK), and 4,000 units to BYD COMPANY (01211.HK). The above companies have all been included on the Pentagon's list of firms allegedly linked to the Chinese military.

Multiple companies applied during the period for approval to ship more than 3.4 million chips to China, documents showed. It remains unclear how many of the approved chips were ultimately delivered to China. The chips involved included NVIDIA's H200 and AMD's equivalent MI325X chips.

NVIDIA said in a statement that the approvals were subject to strict conditions and limited quantities. Although export licenses were granted, the company has stopped shipping H200 chips to China. AMD said it complies with applicable US export control laws and regulations and maintains strict procedures to ensure compliance across its global operations.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:06
NVIDIA Shrs Slump for 6 Straight Days; Mkt Cap Wipes off by USD600B+

NVIDIA (NVDA.US) shares elevated in early trading on Thursday, partly propelled by optimism surrounding Anthropic's IPO, but turned lower again by midday. The stock closed at USD145.98 last night, down 3.3%. The company's market cap has wiped off by more than USD600 billion over the past six trading days.

Analysts said multiple factors are weighing on the stock, including Moody's decision on Wednesday to revise NVIDIA's outlook from Positive to Stable.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]